KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 148 Publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLONpdLUUN3ME2zMlI4OzV{IN88US=> NUTXZYE3W0GQR1XS
HuO-3N1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLoTWM2OD12LkG3NVQzKM7:TR?= NEPufXRUSU6JRWK=
LAMA-84 NXqxUZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\WZ2lEPTB;ND61PFQ3PSEQvF2= Mk[2V2FPT0WU
CAL-72 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXZNJJEUUN3ME21MlQ5ODh2IN88US=> NX;pN3YyW0GQR1XS
LoVo NF3JfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1mzOmlEPTB;Nj65N|I{QSEQvF2= M2jyfHNCVkeHUh?=
HH NGTwcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL5TWM2OD16LkK3OlcyKM7:TR?= NFvydndUSU6JRWK=
SK-MEL-3 NF\iWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfNZohKSzVyPUiuNlg2PzVizszN MnHXV2FPT0WU
KM12 M2\RVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rj[mlEPTB;OT6yNVE1OiEQvF2= MVjTRW5ITVJ?
NCI-H1437 NWfxO|hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDkTWM2OD17LkiwPVch|ryP NGrjZWVUSU6JRWK=
NCI-H1838 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjObGxKSzVyPUGxMlE5PjVizszN NHH1OGxUSU6JRWK=
J-RT3-T3-5 NX;NUYI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHXe5FKSzVyPUGxMlI1OTdizszN MlW2V2FPT0WU
GOTO M1vrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v6XmlEPTB;MUGuOlk6PiEQvF2= MUXTRW5ITVJ?
LB2241-RCC NUTxdWhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLpTWM2OD1zMT63NVg3KM7:TR?= MUDTRW5ITVJ?
ES7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vxbGlEPTB;MUGuO|g5KM7:TR?= M1LsZ3NCVkeHUh?=
KP-N-YS M2\oe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[xW2JvUUN3ME2xNk43OzV2IN88US=> M2DQZnNCVkeHUh?=
CAL-12T MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zpSWlEPTB;MUOuOlE4KM7:TR?= MWDTRW5ITVJ?
COLO-684 M2\yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PFR2lEPTB;MUSuNVU3QSEQvF2= M{DQ[nNCVkeHUh?=
DOK NGqz[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF3LkOzNlkh|ryP NVPi[2VOW0GQR1XS
Hs-578-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln0TWM2OD1zNT60NVgzKM7:TR?= NYf3eopYW0GQR1XS
D-423MG MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TIfWlEPTB;MUWuOVI{PiEQvF2= NITZOYJUSU6JRWK=
DBTRG-05MG NXTqWZBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H1S2lEPTB;MUWuOlEyOSEQvF2= Mkf6V2FPT0WU
VM-CUB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnpWHBTUUN3ME2xOU46QDR7IN88US=> NFPBOIZUSU6JRWK=
KG-1 M1n3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF4LkC5PVYh|ryP M3XtbHNCVkeHUh?=
8305C NYe1NHlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ju[WlEPTB;MU[uNVg5QSEQvF2= NVviRmY2W0GQR1XS
HuH-7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImwdHhKSzVyPUG2MlI3PzRizszN NWLWZVJ[W0GQR1XS
LXF-289 M4jkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXWTWM2OD1zNj6yO|Q4KM7:TR?= MoHkV2FPT0WU
NCI-H1793 NFPlb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXvTWM2OD1zNj60O|EzKM7:TR?= MkezV2FPT0WU
ChaGo-K-1 M{LjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LUOWlEPTB;MU[uOlU3QCEQvF2= MnT1V2FPT0WU
GCIY NWLzOGdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHtR2NPUUN3ME2xOk44QTB3IN88US=> M3;HR3NCVkeHUh?=
SK-MEL-28 NEW5TFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL5epdKSzVyPUG3MlA1PzVizszN M33Z[HNCVkeHUh?=
NCI-SNU-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;wSpNlUUN3ME2xO{4yOjZ7IN88US=> NGK4[GdUSU6JRWK=
CTB-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF5LkKyOVkh|ryP NWTn[Yl3W0GQR1XS
NCI-H82 M3vSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHnd5NUUUN3ME2xO{41PTd|IN88US=> NViwbZBpW0GQR1XS
HCC2998 NIXENIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG4S|RiUUN3ME2xO{43PzN|IN88US=> MlnHV2FPT0WU
NCI-H2030 NEfGb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:0TlRKSzVyPUG4MlE6QTdizszN MV3TRW5ITVJ?
HuP-T3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\xN2lEPTB;MUiuOVg5QCEQvF2= M3i4S3NCVkeHUh?=
697 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;GTWM2OD1zOT6wNlAyKM7:TR?= MnnwV2FPT0WU
MLMA Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXNTWM2OD1zOT6wOVU4KM7:TR?= Ml;EV2FPT0WU
HCC70 M{LBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\Ub2lEPTB;MUmuOFg6KM7:TR?= MkLuV2FPT0WU
A704 M4rYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP5TWM2OD1zOT64N|A2KM7:TR?= M4TKenNCVkeHUh?=
D-283MED M1LUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrBXlhKSzVyPUKwMlU{OzlizszN NWXqfZNvW0GQR1XS
U031 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2yW45QUUN3ME2yNU4yPDh7IN88US=> MX;TRW5ITVJ?
HSC-3 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LXemlEPTB;MkGuNVg{PSEQvF2= NH7GbI9USU6JRWK=
JVM-3 NGfhdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjJcIxKSzVyPUKyMlUxPiEQvF2= MXjTRW5ITVJ?
Mewo MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ{LkWwO|Mh|ryP MX7TRW5ITVJ?
YH-13 NHLDV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ{LkWxNlMh|ryP NVzjV4lIW0GQR1XS
LB1047-RCC NX3ubVZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK5VXNKSzVyPUKyMlU5PzlizszN M{TiTHNCVkeHUh?=
HCC2157 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSxTWM2OD1{Mj64NFU1KM7:TR?= MkXXV2FPT0WU
SNU-449 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ{Lki3OFgh|ryP M1rDXHNCVkeHUh?=
Ramos-2G6-4C10 M3\zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ{Lkm2JO69VQ>? MlvvV2FPT0WU
CHL-1 NXP4OnIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zS[WlEPTB;MkOuO|I6OiEQvF2= M4LR[nNCVkeHUh?=
SK-MEL-30 NHzzV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LtdGlEPTB;MkSuOFY3OiEQvF2= MVTTRW5ITVJ?
PANC-08-13 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTzTWM2OD1{NT6wPVM5KM7:TR?= MUnTRW5ITVJ?
QIMR-WIL MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nzeWlEPTB;MkWuNVg2QCEQvF2= MYTTRW5ITVJ?
BFTC-905 M3jOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf4OXVpUUN3ME2yOU42QTR2IN88US=> NIfNXXJUSU6JRWK=
GI-1 M33NNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDJXXRpUUN3ME2yOU44ODV3IN88US=> MWDTRW5ITVJ?
MDA-MB-415 M4PPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnoOnNKSzVyPUK2MlUxOzNizszN NWiyTWdyW0GQR1XS
GT3TKB MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnlWZVKSzVyPUK2MlU{PDJizszN NFHBcoZUSU6JRWK=
DEL MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ4LkizOVYh|ryP M4DHeXNCVkeHUh?=
KOSC-2 M1rxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPqTWM2OD1{Nj65NFc2KM7:TR?= MlHjV2FPT0WU
RVH-421 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ5LkK5NlEh|ryP MorJV2FPT0WU
EW-13 NI\3ZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXzTWM2OD1{Nz60N|A5KM7:TR?= NYTnNY9LW0GQR1XS
639-V M1m4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DC[GlEPTB;MkeuOVEyQSEQvF2= M3vEOnNCVkeHUh?=
A2780 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ5Lk[0NUDPxE1? Mn;GV2FPT0WU
SW982 NGn0UFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT5[3JiUUN3ME2yO{46ODV{IN88US=> MVjTRW5ITVJ?
SW1710 NFO2V2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXRUpFEUUN3ME2yPE4xQThzIN88US=> M3;xdXNCVkeHUh?=
HCC1569 NWnDSlRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfUTWM2OD1{OD60PFk4KM7:TR?= NVPtSFc6W0GQR1XS
MV-4-11 NX3uZVBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ6LkW3N|Uh|ryP M3rCXHNCVkeHUh?=
BHT-101 M4noWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDmbIlKSzVyPUK4MlY2PzJizszN MnzRV2FPT0WU
Ca9-22 M{LJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqzOIl4UUN3ME2yPE44OTRizszN Mn\RV2FPT0WU
HAL-01 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nIdGlEPTB;MkiuO|YyPSEQvF2= M2rzenNCVkeHUh?=
D-263MG NHvGdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJ7LkO0OEDPxE1? Mn:0V2FPT0WU
NEC8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojETWM2OD1{OT61OVQ5KM7:TR?= Mn7BV2FPT0WU
EKVX NEDQT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjzd2hKSzVyPUOxMlU5PDdizszN M2f5VnNCVkeHUh?=
EM-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXPTWM2OD1|MT62N|A1KM7:TR?= M1[4d3NCVkeHUh?=
MFM-223 NUX4VYhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXS[nRKSzVyPUOxMlgxQThizszN NV7idnZqW0GQR1XS
SK-PN-DW MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISyeGpKSzVyPUOyMlE1ODZizszN MVPTRW5ITVJ?
HuO9 NXn2O2JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELROmJKSzVyPUOyMlUzQDJizszN NWHpb3RYW0GQR1XS
MHH-PREB-1 NYjGdVNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[5d4NKSzVyPUOyMlYzOzRizszN M{jQUnNCVkeHUh?=
OVCAR-4 NVG1c|NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzJeW1KSzVyPUOyMlg{PjNizszN M1PJPHNCVkeHUh?=
NCI-H1648 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS1XotKSzVyPUOyMlg3PTFizszN NH\nNXZUSU6JRWK=
MKN1 M3\qcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN2LkGxNFEh|ryP M1vpcHNCVkeHUh?=
KYSE-450 NGPiTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPCRlU2UUN3ME2zOE43PDR2IN88US=> NX\hdlhUW0GQR1XS
ES8 M1HOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr0TWM2OD1|ND64PVc2KM7:TR?= MnvvV2FPT0WU
MS-1 NX\L[oRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXwcWJjUUN3ME2zOE46PTV2IN88US=> NGW1SnJUSU6JRWK=
HOP-92 M3TS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN3LkmyO|ch|ryP NWnTe4U2W0GQR1XS
SKG-IIIa NG\4NY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H3ZmlEPTB;M{[uNlU3OSEQvF2= MmfYV2FPT0WU
TE-11 M4\GZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfvTWM2OD1|Nj61NlQ{KM7:TR?= MmP5V2FPT0WU
SK-NEP-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qwSWlEPTB;M{euOlc1PCEQvF2= M1vZNHNCVkeHUh?=
DB Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HyfmlEPTB;M{euPVE5PSEQvF2= MkL2V2FPT0WU
IA-LM NWDSVoRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;UfolKSzVyPUO4MlAzOzlizszN MV\TRW5ITVJ?
COLO-829 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO5TWM2OD1|OD60NVU6KM7:TR?= NHe0TWlUSU6JRWK=
TGBC11TKB MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPETWM2OD1|OT6xOFA5KM7:TR?= M{nofnNCVkeHUh?=
CAL-51 M2XNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\6TWM2OD12MD6wOlEzKM7:TR?= NImze45USU6JRWK=
NCI-H2228 NHfBSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuwdW5VUUN3ME20NE4{PjZ{IN88US=> MnXYV2FPT0WU
C32 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDXTWM2OD12MD60NFI1KM7:TR?= NVTjN4NqW0GQR1XS
KU-19-19 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHpc|VKSzVyPUSwMlc3QDNizszN MY\TRW5ITVJ?
KNS-62 M3;i[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHBXWlKSzVyPUSwMlg{QDFizszN NWrpeWxYW0GQR1XS
FADU MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTRzLkK1NFIh|ryP MmGzV2FPT0WU
CAL-33 M3;1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTR{Lk[3OFkh|ryP NGjaT2RUSU6JRWK=
CHP-134 NFjOPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fZd2lEPTB;NEKuPFQ6PiEQvF2= MlG1V2FPT0WU
HDLM-2 NG\DO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTR{LkmwPFQh|ryP M2DKcXNCVkeHUh?=
NBsusSR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPQUVZKSzVyPUSzMlA4OjVizszN NXGzb2Z5W0GQR1XS
SW954 NGrGSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f2R2lEPTB;NEOuNVA2OyEQvF2= MkTPV2FPT0WU
HCC1806 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LoRWlEPTB;NEOuOFEyKM7:TR?= M1rqeXNCVkeHUh?=
VMRC-RCZ M2DQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj0RoNKSzVyPUSzMlQ2QDZizszN NFjVemNUSU6JRWK=
A549 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX75XVM4UUN3ME20N{46OzFizszN NUTEbWtpW0GQR1XS
NKM-1 NX;TUXV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXGWpRKSzVyPUSzMlk2PThizszN MY\TRW5ITVJ?
DMS-273 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTR2Lke1Olch|ryP MlvaV2FPT0WU
TYK-nu MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHBTWM2OD12NT6xNlM1KM7:TR?= MYLTRW5ITVJ?
KALS-1 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXna[Gp3UUN3ME20OU4yPDZizszN MoX6V2FPT0WU
A101D M1LE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[5TlFKSzVyPUS1MlQ1PTZizszN NVLOSlhCW0GQR1XS
G-361 M3SxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DqOmlEPTB;NE[uNlE{QCEQvF2= M2\SR3NCVkeHUh?=
KARPAS-299 NHHaW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO0elJ2UUN3ME20Ok4{PTF4IN88US=> MoS5V2FPT0WU
RS4-11 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzr[o5KSzVyPUS2MlU1OiEQvF2= NIOyenZUSU6JRWK=
HT-1376 M1SzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQTY1KSzVyPUS2Mlc1OjZizszN NX22[I9JW0GQR1XS
SK-N-AS M1z1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrHTWM2OD12Nj63PFIzKM7:TR?= MYXTRW5ITVJ?
MG-63 NUHPSHh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n3fmlEPTB;NE[uPVA{PiEQvF2= NVfVeI1WW0GQR1XS
EPLC-272H NI\0UZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr1TWM2OD12Nj65OVA{KM7:TR?= NILYSHBUSU6JRWK=
BALL-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvMXYtKSzVyPUS3Mlg{OiEQvF2= M36wdXNCVkeHUh?=
LCLC-97TM1 NF\vV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7YTXhKSzVyPUS4MlIxOiEQvF2= MlrEV2FPT0WU
HO-1-N-1 M372Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M331WWlEPTB;NEiuPVY4PiEQvF2= NU\iTmxsW0GQR1XS
MFE-280 NILyTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3tb2VmUUN3ME20PU41PjF5IN88US=> MknZV2FPT0WU
NCI-H526 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTR7LkixOlMh|ryP M2L6cnNCVkeHUh?=
D-566MG M2X0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7WTWM2OD12OT65NFk3KM7:TR?= MWTTRW5ITVJ?
BB30-HNC NHr3fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;SPWlEPTB;NEmuPVQ6QCEQvF2= NGnxXmFUSU6JRWK=
SK-N-DZ NFjsXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvMcZVKSzVyPUWwMlA1QDFizszN MnLnV2FPT0WU
HepG2  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjQc2lKOTEEoN88US=> NFzQc2kzPCCq M174e4Jtd2OtczDTR{1KUUl|LXnu[JVk\WRiUzDwbIF{\SCjcoLld5Q> NVvpZWJqOjV3MkexNlM>
HepG2  NFvCRmpHfW6ldHnvckBCe3OjeR?= MnPmNVDDqM7:TR?= MkHENlQhcA>? M4PP[pN2eHC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdnNib3[gRXROKG:wIGPldlE6QDFuIFPob|Ehd25iU3XyN|Q2NCCFaHuyJI9vKFSqck[4MEBidmRiQ3TrNkBwdiCWeYKxOUBqdmS3Y3XkJIJ6KFOFLVnJTVM> MYqyOVUzPzF{Mx?=
KATO III  NXLJWYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nOXlIvPS93L{euOUDPxE1? NEjnOphFVVOR NGPBfHNmdmijbnPld{B1cGVidH;4bYNqfHlib3[gc4xieGG{aXK= NH;IOYIzPDh2MUexPC=>
hTCEpi NFLjVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrtNVAh|ryP NUnLU49qTE2VTx?= NFrvTIZxemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF? NHfiflIzPDN5MEizOS=>
MCF10A NYf2O4lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNEDPxE1? MoPGNlQhcA>? NY\a[FZzTE2VTx?= NWHqT|Y4eG:2ZX70bYF1\XNidHjlJIN6fG:2b4jpZ4l1gSCxZjDHRS=> NX;JdI9WOjRzNUC1PVU>
HL-60  NHOxUWJHfW6ldHnvckBCe3OjeR?= MYGxNEDPxE1? M1zvSVAvPSCq MnzxSG1UVw>? NGP2R2Nz\WS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kBEcGt{wrC= NILoOoQzOzl|NESxNS=>
MCF-7 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfoNU0yODEQvF2= MlzTNlQhcA>? NGj1e5BHSlN? MYLpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v M3HiV|I{OTh3M{S3
HeLa  M1uzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33wc|EuOTByzszN NWL4TYpSOjRiaB?= NGDLc5ZHSlN? NYXI[4xOcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= MXWyN|E5PTN2Nx?=
SH-SY5Y MWnGeY5kfGmxbjDBd5NigQ>? M1XzVlExyqEQvF5CpC=> NVjCTmVEOjRiaB?= MUXpcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>? NHq5NpEzOjZ{N{K5OC=>
IMR-32 NYTTfnQzTnWwY4Tpc44hSXO|YYm= NFTrW4kyOMLizszNxsA> MlzXNlQhcA>? MkDFbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? MnXQNlI3Ojd{OUS=
A549 M1nlbmZ2dmO2aX;uJGF{e2G7 M3TIPFExyqEQvF5CpC=> NXztcJNvOSCq MV\zeZBxemW|c3XzJG5idm9vQ3:tbY5lfWOnZDDwOVMh[WOldX31cIF1cW:w M2f0S|IzPTV7M{Kx
T47D  MYPGeY5kfGmxbjDBd5NigQ>? M3H0c|IxyqCvTR?= MYmyOEBp MkLNSG1UVw>? M2THbpBz\X[nboTzJGlTNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gTe67Ss7z NXPqVmlbOjFzNES4NFU>
A29 MEF M3nYWWZ2dmO2aX;uJGF{e2G7 NULQfXhROTEEoN88UeKh NV\pPZhSOWh? MmfpZoxw[2u|wrD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGtdDDheEBU\XJ2N{RCpC=> M4\LVFIxODV|N{ix
MDA-MB-453  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK1MVQxKM7:TR?= NUXzSFFwPzJiaB?= NEDWUGJKSzVyIH;mJFExKM7:TR?= MoXyNlAxPTN5OEG=
PC-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P5blUuPDBizszN M4rQflczKGh? MV;JR|UxKG:oIEGwJO69VQ>? NXrzdVZnOjByNUO3PFE>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]
- Collapse

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]
- Collapse
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]
- Collapse
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing. 		3.95 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2
CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

  • AZD6738(Ceralasertib) New

    AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • VE-821

    VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.

  • KU-60019

    KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.

    Features:Improved analog of KU-55933, and is more effective at blocking ATM-mediated DDR events.

  • Berzosertib (VE-822，VX970|M6620)

    VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

    Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.

  • Chloroquine diphosphate

    Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator.

  • AZ20

    AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.

    Features:AZ20 is the first reported inhibitor of ATR protein kinase demonstrating tumor growth inhibition in vivo.

  • CP-466722

    CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.

  • ETP-46464

    ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

    Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID